$4M Grant Fuels AC Immune's Parkinson's Drug Trial Extension
ACIU sits 35% above its 52-week low of $1.65 on elevated volume (2.0× avg).
Summary
AC Immune secured a $4 million research grant from the Goradia Family Foundation to extend Part 1 of its Phase 2 VacSYn trial for ACI-7104, a Parkinson's disease immunotherapy. This non-dilutive funding will support an additional two years of data collection on long-term safety and efficacy. The news follows positive interim Phase 2 results for ACI-7104 reported in March and provides a positive contrast to the company's recent proposal for a potentially dilutive capital raise. This extension is critical for gathering comprehensive data needed for the drug's continued development and potential future regulatory submissions.
At the time of this announcement, ACIU was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $215.8M. The 52-week trading range was $1.65 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.